Matthew Gall was named Chief Financial Officer of Tango Therapeutics, Inc., effective April 15, 2026. As of November 7, 2026, Tango Therapeutics, Inc. has reported 4 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 15, 2026 to August 6, 2026, naming 3 appointments and 2 departures (Form 8-K, April 15, 2026).
Who owns Tango Therapeutics, Inc.?
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Tango Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-08-06
- · In / out: In · Person: Robert Azelby · Role: Director · Effective: 2026-06-19 · 8-K, 2026-06-23
- · In / out: Out · Person: Alexis Borisy · Role: Lead Independent Director · Effective: 2026-05-13 · 8-K, 2026-05-13
- · In / out: In · Person: Matthew Gall · Role: Chief Financial Officer · Effective: 2026-04-15 · 8-K, 2026-04-15
Tango Therapeutics, Inc. reported changes in 4 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-15 to 2026-08-06. They name 5 people, with 3 appointments and 2 departures. Every row below is cited to the filing it comes from, and this page adds each new change as Tango Therapeutics, Inc. files it.
Also on the record for Tango Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 6, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 15% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G, by THE GOLDMAN SACHS GROUP, INC. | 6% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Farallon Capital Management, L.L.C. | 9.8% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Nextech Crossover I GP S.a. r.l. | — | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by TCG Crossover GP II, LLC | 7% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Woodline Partners LP | 2.5% of the class | 5%+ stakes | Source |
| August 12, 2026 | Stake report, Schedule 13G/A, by Adage Capital Management, L.P. | 3.44% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by RTW Investments, LP | 9.3% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Nextech Crossover I GP S.a. r.l. | 5.1% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by TCG Crossover GP II, LLC | 8.1% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Woodline Partners LP | 5.6% of the class | 5%+ stakes | Source |
| May 13, 2026 | Stake report, Schedule 13G/A, by Adage Capital Management, L.P. | 8.98% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Tango Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Tango Therapeutics, Inc. and the records around it.
Tango Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Form D filing Oct 2025
- Who owns it
Companies that share a holder
- Third Rock Ventures IV, L.P. also filed stake reports on 1 other company: Maze Therapeutics, Inc. (Feb 2026)
- Nextech Crossover I GP S.a. r.l. also filed stake reports on 2 other companies: ORIC Pharmaceuticals, Inc. (Aug 2025)
- Farallon Capital Management, L.L.C. also filed stake reports on 18 other companies: EXELIXIS, INC. (Nov 2026), ENANTA PHARMACEUTICALS INC (Aug 2026), InflaRx N.V. (Aug 2026)
Watch Tango Therapeutics, Inc.
Get an email when Tango Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Tango Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Tango Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Tango Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 36 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-08-06 | Reported | not named in the filing | 8-K, 2026-08-06 | ||
| 2026-06-23 | In | Director | 2026-06-19 | 8-K, 2026-06-23 | |
| 2026-05-13 | Out | Lead Independent Director | 2026-05-13 | 8-K, 2026-05-13 | |
| 2026-05-13 | Out | 2026-05-13 | 8-K, 2026-05-13 | ||
| 2026-04-15 | In | Chief Financial Officer | 2026-04-15 | 8-K, 2026-04-15 | |
| 2026-04-15 | In | 2026-04-15 | 8-K, 2026-04-15 |
Who leads Tango Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Robert Azelby, appointed, effective 2026-06-19 (filed 2026-06-23).
- Lead Independent Director: Alexis Borisy, departure reported, effective 2026-05-13 (filed 2026-05-13). No successor is named in these filings.
- Chief Financial Officer: Matthew Gall, appointed, effective 2026-04-15 (filed 2026-04-15).
New leaders reset buying decisions — get the Full Report on Tango Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Tango Therapeutics, Inc., with the record behind each one.
Find candidates like Director at Tango Therapeutics, Inc.Every change, in the filing's words
Reported
Consistent with the terms of the Employment Agreement, Dr. Weber is deemed to have resigned from all officer and board member positions, including as a member of Company's board of directors (the "Board") upon the termination of Dr. Weber's employment.
- Dr. Barbara Weber's employment with Tango Therapeutics, Inc. (the "Company") as its Executive Chair ended on August 3, 2026 in accordance with the terms of her Amended and Restated Employment Agreement dated January 8, 2026 (the "Employment Agreement").
- Dr. Weber's resignation was not a result of any disagreement with the Company on any matter relating to the Company's operations, practices or policies.
- In order to receive the foregoing benefits, Dr. Weber must execute and not revoke a Separation Agreement as set forth in the Employment Agreement.
Appointed: Robert Azelby, Director, effective 2026-06-19
Effective June 19, 2026, the Board appointed Robert Azelby as a director of the Company to fill the newly created vacancy on the Board resulting from the increase to the board size.
- On June 19, 2026, the Board of Directors (the "Board") of Tango Therapeutics, Inc. (the "Company") increased the number of directors of the Company to seven (7).
- Mr. Azelby will serve as a Class II director until his term expires at the 2029 annual meeting of stockholders at which time he will stand for election by the Company's stockholders.
- The Board determined that Mr. Azelby is independent under the listing standards of The Nasdaq Stock Market.
- The Board also approved the appointment of Mr. Azelby as a member of the Compensation Committee of the Board (the "Compensation Committee") and as a member of the Nominating and Corporate Governance Committee of the Board (the "NCG Committee"), effective as of June 23, 2026.
- In accordance with the Company's compensation program for non-employee directors, Mr. Azelby will receive an equity award consisting of a stock option to purchase 35,910 shares of the Company's common stock, par value $0.001 per share ("Common Stock") at an exercise price of $27.97 per share and a restricted stock unit ("RSU") award to acquire 5,740 shares of Common Stock.
Departing: Alexis Borisy, Lead Independent Director, effective 2026-05-13
(b) Resignation of Alexis Borisy On May 12, 2026, Alexis Borisy resigned from the Company's Board of Directors (the "Board"), as Lead Independent Director of the Board, and as the Chairperson of the Compensation Committee of the Board (the "Compensation Committee") and as a member thereof, in each case effective as of May 13, 2026.
Departing: Kanishka Pothula, effective 2026-05-13
Resignation of Kanishka Pothula Also on May 12, 2026, Kanishka Pothula resigned from the Board and as a member of the Nominating and Corporate Governance Committee of the Board (the "NCG Committee"), in each case effective as of May 13, 2026.
- Mr. Borisy's resignation was not a result of any disagreement with the Company on any matter relating to the Company's operations, practices or policies.
- Mr. Pothula's resignation was not a result of any disagreement with the Company on any matter relating to the Company's operations, practices or policies.
- In connection with Mr. Borisy's and Mr. Pothula's resignations from the Board, the Board appointed Sung Lee as Lead Independent Director of the Board and the Chairperson of the Compensation Committee and as a member thereof, each effective as of May 13, 2026.
- The Compensation Committee now consists of Sung Lee, John Ketchum and Mace Rothenberg, M.D. The Board also approved the appointment of Sung Lee as a member of the NCG Committee, effective as of May 13, 2026.
- The NCG Committee now consists of Mace Rothenberg, Sung Lee and Lesley Ann Calhoun.
Appointed: Matthew Gall, Chief Financial Officer, effective 2026-04-15
On April 10, 2026, the Board appointed Matthew Gall, MBA, 49, as the Company's Chief Financial Officer and principal financial officer effective as of April 15, 2026.
Appointed: Jessica Newcomb, effective 2026-04-15
On April 10, 2026, the Board appointed Jessica Newcomb, 40, to serve as the Company's principal accounting officer effective as of April 15, 2026.
- Departure of Chief Financial Officer On April 10, 2026, the board of directors (the "Board") of Tango Therapeutics, Inc. (the "Company") determined that Daniella Beckman will no longer serve as the Company's Chief Financial Officer, principal accounting officer and principal financial officer, effective as of April 15, 2026.
- Mr. Gall previously served as Chief Financial Officer of Kalaris Therapeutics, Inc. from November 2025 to April 2026.
- Prior to that, Mr. Gall served as the Chief Financial Officer of iTeos Theraputics, Inc., a clinical-stage biopharmaceutical company, from June 2020 to August 2025 and he held various roles at Sarepta Therapeutics, Inc., a commercial-stage biotechnology company, from January 2012 to June 2020.
- Mr. Gall holds a B.S. in Business Administration from Bowling Green State University and an M.B.A. from The University of Chicago Booth School of Business.
- In connection with his appointment as Chief Financial Officer, Mr. Gall entered into an employment agreement with the Company (the "Employment Agreement"), effective April 15, 2026.
- Pursuant to the terms of the Employment Agreement, Mr. Gall will be entitled to: Annual base salary of $540,000; Target cash bonus opportunity of 40% of his current annual base salary, pro-rated for any partial calendar year of service.
Tools for this story
Each opens in a new tab, filled in for Tango Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.